Florida Cancer Specialists & Research Institute

CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.

NCCN concordance won't ensure coverage; OAB risk tied to income; 91% offer bispecifics; ruxolitinib spend hits $49.6M; TALK SAFE Act aids telepsychiatry.

Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.

Community oncology faces high costs and staffing hurdles for trials; Lucio N. Gordan, MD, urges pragmatic designs matching real-world patients.

Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.

Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.

Seven oncology leaders reflect on lasting gains in patient care, cost awareness, and collaboration, and what was lost when CMS walked away.

Although they covered diverse topics across the cancer continuum, the event’s 4 panel discussions shared a common focus on advancing more equitable and coordinated care.

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

Ameet Patel, MD, discusses scaling CAR T-cell therapy and bispecific therapies to improve access and potentially cure multiple myeloma.

Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.

Explore the complexities of modern oncology, including precision medicine, CAR T-cell therapies, and challenges in breast cancer care and payer friction.

A study finds that community oncology practices limit financial toxicity for patients with cancer, offering significant cost savings compared with hospital outpatient settings.

In a time of skyrocketing oncology drug costs, the role of pharmacists in managing patients’ treatment and keeping care in the outpatient setting is more urgent than ever.

The FDA's removal of REMS for CAR T-cell therapies enhances access for community oncology, paving the way for innovative treatments and improved patient outcomes.

Community oncology faces significant challenges from the Inflation Reduction Act's (IRA) drug pricing changes, risking financial stability and patient access to care.

Experts at the Community Oncology Conference discuss innovative patient navigation programs, emphasizing technology's role and the importance of human connection in cancer care.

The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.

Investigators from Florida Cancer Specialists & Research Institute explored questions surrounding minimal residual disease (MRD) negativity testing in an abstract presented at the International Myeloma Society 21st Annual Meeting & Exposition.

The $2.49 billion cash purchase will give McKesson about 70% ownership of Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures).

Florida Cancer Specialists & Research Institute launches a new precision medicine venture; Tennessee Oncology announces promotions.

As pressure from the Biden administration on UnitedHealth Group increases, physicians' groups weigh in following the unprecedented hack on Change Healthcare.

Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute, shares her thoughts on future directions in value-based oncology care and research.

Business and practice updates from our Strategic Alliance Partners.